Compound ID	CDAMM01502
Common name	Sitoindoside I
IUPAC name	[6-[[17-(5-ethyl-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl hexadecanoate
Molecular formula	C₅₁H₉₀O₇

Experimental data

Retention time	18.63
Adduct	[M+Na]+
Actual mz	837.665
Theoretical mz	837.658
Error	8.34
Ionizaton mode	Positive
Instrument type	LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score	6.4707

Identifiers and class information

Inchi key	JCLYMCVRBRHEHI-UHFFFAOYNA-N
Smiles	O=C(OCC1OC(OC2CC3=CCC4C(CCC5(C)C(CCC45)C(C)CCC(CC)C(C)C)C3(C)CC2)C(O)C(O)C1O)CCCCCCCCCCCCCCC
Superclass	Lipids and lipid-like molecules
Class	Steroids and steroid derivatives

Plant source

Cinnamomum tamala (Buch.-Ham.) T.Nees & C.H.Eberm.

External sources

HMDB ID	HMDB0030836
KNApSAcK ID	C00035875
FooDB ID	FDB002792
DrugBank ID
ChEBI ID	CHEBI:67595
Pubchem Compound ID	13051622
PlantCyc ID
UNPD ID	UNPD158987
Coconut ID	CNP0244079
LipidMAPS ID	LMST01040198
NANPDB ID	NANPDB_2479

Pharmacokinetic properties

Number of descriptor values(#stars)	13
Number of non-conjugated amine groups (#amine)	0
Number of amidine and guanidine groups (#amidine)	0
Number of carboxylic acid groups (#acid)	0
Number of non-conjugated amide groups (#amide)	0
Number of rotatable bonds (#rotor)	27
Number of reactive functional groups (#rtvFG)	2
Predicted central nervous system activity (CNS)	-2
Molecular weight (mol_MW)	815.268
Computed dipole moment(dipole)	3.541
Total solvent accessible surface area (SASA)	1485.13
Hydrophobic component of SASA (FOSA)	1300.8
Hydrophilic component of SASA (FISA)	162.941
Pie component of the SASA (PISA)	21.39
Weakly polar component of the SASA (WPSA)	0
Total solvent accesible volume (volume)	2860.52
Number of hydrogen bond donors (donorHB)	3
Number of hydrogen bond acceptors (accptHB)	10.5
Free energy of solvation of dipole (dip^2/V)	0.0043836
Index of cohesive interaction in solids (ACxDN^.5/SA)	0.0122457
Globularity descriptor (glob)	0.656191
Predicted polarizability in cubic angstroms (QPpolrz)	91.192
Predicted hexadecane/gas partition coefficient (QPlogPC16)	28.869
Predicted octanol/gas partition coefficient (QPlogPoct)	39.745
Predicted water/gas partition coefficient (QPlogPw)	13.328
Predicted octanol/water partition coefficient (QPlogPo/w)	11.384
Predicted aqueous solubility (QPlogS)	-14.486
Conformation-independent predicted aqueous solubility (CIQPlogS)	-11.528
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)	-7.197
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)	282.312
Predicted brain/blood partition coefficient (QPlogBB)	-3.587
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)	126.082
Predicted skin permeability, log Kp (QPlogKp)	-1.855
PM3 calculated ionization potential (IP(ev))	9.364
PM3 calculated electron affinity (EA(eV))	-0.633
Number of likely metabolic reactions (#metab)	6
Prediction of binding to human serum albumin (QPlogKhsa)	2.944
Predicted qualitative human oral absorption (HumanOralAbsorption)	1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)	100
Solvent-accessible surface area of fluorine atoms (SAFluorine)	0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)	0
Van der Waals surface area (PSA)	114.042
Number of nitrogen and oxygen atoms (#NandO)	7
Number of violations of Lipinskiâ€™s rule of five (RuleOfFive)	2
Number of violations of Jorgensenâ€™s rule of three (RuleOfThree)	1

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID	Gene name	Target name	TTD_ID	Prediction source
P00915	CA1	Carbonic anhydrase I	T13201	SEA
P00918	CA2	Carbonic anhydrase II	T20401	SEA
Q15125	EBP	Anti-estrogen binding site (AEBS)	T25317	SEA
Q16739	UGCG	Ceramide glucosyltransferase	T14908	SEA
Q96RI1	NR1H4	Bile acid receptor FXR	T51426	SEA
P31213	SRD5A2	Steroid 5-alpha-reductase 2	T71390	SEA
Q92731	ESR2	Estrogen receptor beta	T80896	SEA
P08185	SERPINA6	Corticosteroid binding globulin	T88452	SEA
P18405	SRD5A1	Steroid 5-alpha-reductase 1	T70309	SEA
Q9UHC9	NPC1L1	Niemann-Pick C1-like protein 1	T33901	SEA
P30307	CDC25C	Dual specificity phosphatase Cdc25C	T40569	SEA
Q8TDU6	GPBAR1	G-protein coupled bile acid receptor 1	T86273	SEA
Q13133	NR1H3	LXR-alpha	T52297	SEA
P11413	G6PD	Glucose-6-phosphate 1-dehydrogenase	T63484	SEA
P05093	CYP17A1	Cytochrome P450 17A1	T89041	SEA
P15692	VEGFA	Vascular endothelial growth factor A	T20761	SEA
P05230	FGF1	Acidic fibroblast growth factor	T18639	SEA
Q12908	SLC10A2	Ileal bile acid transporter	T24982	SEA
P60568	IL2	Interleukin-2	T61698	SEA
P35398	RORA	Nuclear receptor ROR-alpha	T43206	SEA
P29317	EPHA2	Ephrin type-A receptor 2	T57278	SEA
P54756	EPHA5	Ephrin type-A receptor 5	T18474	SEA
P54764	EPHA4	Ephrin type-A receptor 4	T70234	SEA
P54753	EPHB3	Ephrin type-B receptor 3	T56121	SEA
Q14973	SLC10A1	Bile acid transporter	T99189	SEA
P29322	EPHA8	Ephrin type-A receptor 8	T58266	SEA
Q15375	EPHA7	Ephrin type-A receptor 7	T57006	SEA
O15439	ABCC4	Multidrug resistance protein 4	T39919	SEA

Target associated diseases

TTD_ID	Disease_ID	Disease name	ICD_11	Uniprot ID	Gene names
T13201	DI0166	Glaucoma	[ICD-11: 9C61]	P00915	CA1
T13201	DI0372	Seborrhoeic dermatitis	[ICD-11: EA81]	P00915	CA1
T20401	DI0046	Bacterial infection	[ICD-11: 1A00-1C4Z]	P00918	CA2
T20401	DI0137	Essential hypertension	[ICD-11: BA00]	P00918	CA2
T20401	DI0166	Glaucoma	[ICD-11: 9C61]	P00918	CA2
T20401	DI0175	Heart failure	[ICD-11: BD10-BD1Z]	P00918	CA2
T20401	DI0214	Insomnia	[ICD-11: 7A00-7A0Z]	P00918	CA2
T20401	DI0372	Seborrhoeic dermatitis	[ICD-11: EA81]	P00918	CA2
T25317	DI0366	Rheumatoid arthritis	[ICD-11: FA20]	Q15125	EBP
T14908	DI0242	Lysosomal disease	[ICD-11: 5C56]	Q16739	UGCG
T14908	DI0257	Metabolic disorder	[ICD-11: 5C50-5D2Z]	Q16739	UGCG
T51426	DI0043	Autoimmune liver disease	[ICD-11: DB96]	Q96RI1	NR1H4
T51426	DI0077	Cholelithiasis	[ICD-11: DC11]	Q96RI1	NR1H4
T51426	DI0320	Osteoarthritis	[ICD-11: FA00-FA05]	Q96RI1	NR1H4
T71390	DI0348	Prostate hyperplasia	[ICD-11: GA90]	P31213	SRD5A2
T80896	DI0062	Breast cancer	[ICD-11: 2C60-2C6Y]	Q92731	ESR2
T80896	DI0108	Cushing syndrome	[ICD-11: 5A70]	Q92731	ESR2
T80896	DI0254	Menopausal disorder	[ICD-11: GA30]	Q92731	ESR2
T80896	DI0432	Vasomotor/allergic rhinitis	[ICD-11: CA08]	Q92731	ESR2
T88452	DI0037	Asthma	[ICD-11: CA23]	P08185	SERPINA6
T88452	DI0339	Postoperative inflammation	[ICD-11: 1A00-CA43]	P08185	SERPINA6
T88452	DI0362	Respiratory system disease	[ICD-11: CB40-CB7Z]	P08185	SERPINA6
T70309	DI0347	Prostate disease	[ICD-11: GA91]	P18405	SRD5A1
T33901	DI0188	Hyper-lipoproteinaemia	[ICD-11: 5C80]	Q9UHC9	NPC1L1
T86273	DI0417	Type 2 diabetes mellitus	[ICD-11: 5A11]	Q8TDU6	GPBAR1
T52297	DI0117	Depression	[ICD-11: 6A70-6A7Z]	Q13133	NR1H3
T63484	DI0086	Chronic obstructive pulmonary disease	[ICD-11: CA22]	P11413	G6PD
T89041	DI0346	Prostate cancer	[ICD-11: 2C82]	P05093	CYP17A1
T20761	DI0095	Colorectal cancer	[ICD-11: 2B91]	P15692	VEGFA
T20761	DI0365	Retinopathy	[ICD-11: 9B71]	P15692	VEGFA
T20761	DI0430	Vascular system developmental anomaly	[ICD-11: LA90]	P15692	VEGFA
T18639	DI0081	Chronic arterial occlusive disease	[ICD-11: BD4Z]	P05230	FGF1
T18639	DI0102	Coronary atherosclerosis	[ICD-11: BA52]	P05230	FGF1
T24982	DI0349	Pruritus	[ICD-11: EC90]	Q12908	SLC10A2
T61698	DI0275	Multiple sclerosis	[ICD-11: 8A40]	P60568	IL2
T61698	DI0361	Renal cell carcinoma	[ICD-11: 2C90]	P60568	IL2
T43206	DI0235	Liver cancer	[ICD-11: 2C12]	P35398	RORA
T43206	DI0417	Type 2 diabetes mellitus	[ICD-11: 5A11]	P35398	RORA
T57278	DI0060	Brain cancer	[ICD-11: 2A00]	P29317	EPHA2
T57278	DI0391	Solid tumour/cancer	[ICD-11: 2A00-2F9Z]	P29317	EPHA2
T70234	DI0391	Solid tumour/cancer	[ICD-11: 2A00-2F9Z]	P54764	EPHA4
T99189	DI0179	Hepatitis virus infection	[ICD-11: 1E50-1E51]	Q14973	SLC10A1